サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726374

抗凝固剤の世界市場：市場規模・シェア・動向分析 (薬剤カテゴリー別・投与経路別・用途別・地域別)、セグメント別予測 (2025年～2030年)

Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 125 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
抗凝固剤の世界市場：市場規模・シェア・動向分析 (薬剤カテゴリー別・投与経路別・用途別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月24日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗凝固剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗凝固剤の市場規模は2025年から2030年にかけてCAGR 4.8%を記録し、2030年までに471億米ドルに達する見込みです。

同市場は主に、心血管疾患（CVDs）の有病率の増加と高齢化人口の増加によって牽引されています。WHOによると、2019年、CVDは世界中で死亡の大半を引き起こし、死亡者数は1,790万人で、これは世界の死亡者数の32％にあたる。このうち85％は心臓発作と脳卒中によるものです。さらに、非伝染性疾患による1,700万人の早期死亡のうち、38％がCVDによるものでした。

さらに、座りっぱなしのライフスタイルは、運動不足による血栓の世界的増加に大きく寄与しており、抗凝固剤の需要に拍車をかけています。運動不足は、肺塞栓症（PE）や深部静脈血栓症（DVT）を含む静脈血栓塞栓症（VTE）のリスク上昇に関連しています。DVTは脚の深部静脈に血栓ができたときに発症し、PEは深部静脈から肺に血栓が移動したときに発症します。米国国立医学図書館によると、DVTとPEを含むVTEは米国で年間約90万人に影響を及ぼしています。その結果、数十万人が入院し、約30万人が死亡しています。VTEの有病率の増加と、効果的な治療オプションに対する需要の高まりが市場を押し上げると予想されます。

さらに、技術革新の促進、抗凝固剤治療の有効性と安全性の向上、患者のモニタリングと転帰の改善により、抗凝固剤市場の活性化に大きな役割を果たしています。創薬および薬剤開発の進歩により、半減期の延長、他の薬剤との相互作用の低減、出血リスクの低減などの特性が改善された新規抗凝固剤が生み出されています。これらの新規抗凝固剤は、患者により多くの治療選択肢を提供し、より良い治療成績をもたらします。NIHによれば、遺伝子治療は血栓治療のための新しいアプローチであり、遺伝子を用いて血栓の原因となる根本的な遺伝子の欠陥を修正するものです。このアプローチはまだ開発の初期段階ですが、血栓の効果的な治療法となる可能性を秘めています。例えば、2022年11月、FDAは第IX因子製剤を予防的に使用し、重篤な出血を繰り返している血友病Bの成人患者を治療する遺伝子治療薬Hemgenixを承認しました。これは、血液凝固第IX因子の遺伝子を肝臓に投与する1回限りの遺伝子治療です。

抗凝固剤市場レポートハイライト

  • 薬剤カテゴリー別では、新規経口抗凝固剤（NOAC）セグメントが2024年の売上高シェア57.2%で世界の抗凝固剤業界を支配しています。ヘパリンセグメントは予測期間中に大きく成長すると予測されています。
  • 経口抗凝固剤は、2024年に世界の抗凝固剤産業で最大の収益シェアを占めました。投与経路に基づくと、注射用抗凝固剤セグメントは2025年から2030年にかけて成長を遂げると予測されています。
  • 心房細動/心筋梗塞（心臓発作）セグメントは、2024年に世界の抗凝固剤業界を支配しました。深部静脈血栓症（DVT）は予測期間中に大きな成長が見込まれます。
  • 北米は2024年の売上高シェア51.2%で世界の抗凝固剤業界を支配。アジア太平洋の抗凝固剤市場は予測期間中にCAGR 6.1%で最速の成長が予測されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 抗凝固剤市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 抗凝固剤市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗凝固剤市場：薬剤カテゴリー別の推定・動向分析

  • 薬剤カテゴリー別のダッシュボード
  • 抗凝固剤市場：変動分析、薬剤カテゴリー別
  • 世界の抗凝固剤の市場規模と動向分析：薬剤カテゴリー別（2018～2030年）
  • 新規経口抗凝固剤（NOAC）
    • エリキス
    • ザレルト
    • サヴァイサ＆リクシアナ
    • プラダクサ
  • ビタミンK拮抗薬
  • 直接トロンビン阻害剤
  • ヘパリン
    • 種類
    • 原料

第5章 抗凝固剤市場：投与経路別の推定・動向分析

  • 投与経路別のダッシュボード
  • 抗凝固剤市場：変動分析、投与経路別
  • 世界の抗凝固剤の市場規模と動向分析：投与経路別（2018～2030年）
  • 経口抗凝固剤
  • 注射抗凝固剤

第6章 抗凝固剤市場：用途別の推定・動向分析

  • 用途別のダッシュボード
  • 抗凝固剤市場：変動分析、用途別
  • 世界の抗凝固剤の市場規模と動向分析：用途別（2018～2030年）
  • 心房細動/心筋梗塞（心臓発作）
  • 深部静脈血栓症（DVT）
  • 肺塞栓症
  • その他の用途

第7章 抗凝固剤市場：地域別の推定・動向分析

  • 市場ダッシュボード：地域別
  • 市場シェア分析：地域別（2024年・2030年）
  • 抗凝固剤市場：主なポイント、地域別
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 最近の動向と影響分析：主な市場参入企業別
  • 企業/競合の分類
  • ベンダー情勢
    • 主要企業のヒートマップ分析（2024年）
  • 企業プロファイル
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 Global anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 8 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 11 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 Europe anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 21 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 23 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 24 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 27 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 29 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 30 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 32 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 33 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 35 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 36 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 42 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 43 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 46 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 48 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 49 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 52 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 55 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 57 Latin America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 58 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 59 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 61 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 62 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Brazil surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 64 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 65 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Argentina surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 67 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 68 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 71 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 72 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 77 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 78 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Anticoagulants market: market outlook
  • Fig. 10 Anticoagulants competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Anticoagulants market driver impact
  • Fig. 16 Anticoagulants market restraint impact
  • Fig. 17 Anticoagulants market strategic initiatives analysis
  • Fig. 18 Anticoagulants market: Drug category movement analysis
  • Fig. 19 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 21 Eliquis market estimates and forecast, 2018 - 2030
  • Fig. 22 Xarelto market estimates and forecast, 2018 - 2030
  • Fig. 23 Savaysa & lixiana market estimates and forecast, 2018 - 2030
  • Fig. 24 Pradaxa market estimates and forecast, 2018 - 2030
  • Fig. 25 Vitamin K Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 26 Direct Thrombin Inhibitors market estimates and forecast, 2018 - 2030
  • Fig. 27 Heparin market estimates and forecast, 2018 - 2030
  • Fig. 28 Low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 29 Ultra-low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 30 Unrationed heparin market estimates and forecast, 2018 - 2030
  • Fig. 31 Heparin sources market estimates and forecast, 2018 - 2030
  • Fig. 32 Porcine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 33 Bovine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 34 Other heparin market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 37 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 38 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 39 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 40 Anticoagulants market: Application movement analysis
  • Fig. 41 Anticoagulants market: Application outlook and key takeaways
  • Fig. 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 44 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 45 Other applications market estimates and forecasts,2018 - 2030
  • Fig. 46 Global anticoagulants market: Regional movement analysis
  • Fig. 47 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 55 France market estimates and forecasts, 2018 - 2030
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 59 China market estimates and forecasts, 2018 - 2030
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 61 India market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market size is expected to reach USD 47.10 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Heparin segment is projected to experience significant growth over the forecast period.
  • Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030.
  • The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period.
  • North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. Asia Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug category outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Segment Dashboard
  • 4.2. Anticoagulants Market: Drug Category Movement Analysis
  • 4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2018 to 2030 (USD Million)
  • 4.4. Novel Oral Anticoagulants (NOACs)
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Eliquis
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Xarelto
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Savaysa & lixiana
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Pradaxa
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Vitamin K Antagonist
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Direct Thrombin Inhibitors
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Heparin
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Type
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.2. Low Molecular Weight Heparin
        • 4.7.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.3. Ultra-low Molecular Weight Heparin
        • 4.7.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.4. Unfractionated Heparin
        • 4.7.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Source
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.2. Porcine
        • 4.7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.3. Bovine
        • 4.7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.4. Others
        • 4.7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Anticoagulants Market: Route of Administration Movement Analysis
  • 5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Anticoagulants
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Anticoagulants
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Anticoagulants Market: Application Movement Analysis
  • 6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.5. Deep Vein Thrombosis (DVT)
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.6. Pulmonary Embolism
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.7. Other Applications
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. China
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Aspen Holdings
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bristol-Myers Squibb Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Eisai Co., Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives